PLAUR facilitates the progression of clear cell renal cell carcinoma by activating the PI3K/AKT/mTOR signaling pathway
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Upregulated PLAUR promotes clear cell renal cell carcinoma (ccRCC) progression by activating the PI3K/AKT/mTOR pathway. Targeting PLAUR may offer a new strategy for ccRCC treatment and diagnosis.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Research
Background
- Plasminogen activator urokinase receptor (PLAUR) is upregulated in various tumors, correlating with malignant cell phenotypes.
- Its role in clear cell renal cell carcinoma (ccRCC) and mechanisms of tumor promotion require investigation.
Purpose Of The Study
- To investigate the relationship between PLAUR and ccRCC.
- To explore PLAUR's potential mechanism in promoting ccRCC progression.
Main Methods
- Analysis of PLAUR expression and clinical significance in ccRCC using TCGA data.
- qRT-PCR and IHC to assess PLAUR in ccRCC tissues versus adjacent tissues.
- In vitro experiments to evaluate PLAUR suppression effects on ccRCC cell behavior and PI3K/AKT/mTOR pathway activation.
Main Results
- PLAUR was significantly upregulated in ccRCC, associated with poorer prognosis.
- PLAUR knockdown attenuated ccRCC cell proliferation, migration, and invasion.
- PLAUR suppression induced apoptosis, modulated cell cycle, inhibited EMT, and deactivated the PI3K/AKT/mTOR pathway.
Conclusions
- PLAUR promotes ccRCC progression, potentially via PI3K/AKT/mTOR pathway activation.
- PLAUR serves as a potential biomarker for ccRCC identification and prediction.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...